EW
CLDX icon

Evoke Wealth’s Celldex Therapeutics CLDX Stock Holding History

Evoke Wealth’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8
Closed – – 508
2022
Q3 		$0 Hold
8
– – ﹤0.01% 1185
2022
Q2 		$0 Hold
8
– – ﹤0.01% 1184
2022
Q1 		$0 Hold
8
– – ﹤0.01% 1178
2021
Q4 		$0 Hold
8
– – ﹤0.01% 1191
2021
Q3 		$0 Hold
8
– – ﹤0.01% 1155
2021
Q2 		$268K Hold
8
– – 0.01% 309
2021
Q1 		$0 Hold
8
– – ﹤0.01% 1173
2020
Q4 		$0 Hold
8
– – ﹤0.01% 1048
2020
Q3 		$0 Hold
8
– – ﹤0.01% 1034
2020
Q2 		$0 Hold
8
– – ﹤0.01% 1088
2020
Q1 		$13 Hold
8
– – ﹤0.01% 1120
2019
Q4 		$18 Hold
8
– – ﹤0.01% 1248
2019
Q3 		$17 Buy
+8
New +$19 ﹤0.01% 1403

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Evoke Wealth's CLDX Position: Q4 2022 in Review

Evoke Wealth sold out of Celldex Therapeutics (CLDX) in Q4 2022, closing a stake of 8 shares.

Evoke Wealth first reported a position in CLDX in Q3 2019 and held it in 13 quarters. The position peaked at $268K in Q2 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q4 2022.

  • Evoke Wealth reported no remaining Celldex Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Evoke Wealth sold 8 Celldex Therapeutics shares in Q4 2022.
  • Evoke Wealth first reported a position in Celldex Therapeutics in Q3 2019 and held it in 13 quarters.
  • Evoke Wealth's Celldex Therapeutics position peaked at $268K in Q2 2021.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2022.

Based on Evoke Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.